Medicine Shortage Communication

October 2025

Victoza 6 mg/mL solution for injection in pre-filled pen (liraglutide): Risk of supply shortage due to marketing cessation (discontinuation)

Dear Healthcare Professional,

Novo Nordisk AS in agreement with the European Medicines Agency and the Maltese Medicines Authority is notifying healthcare professionals about the marketing—cessation (discontinuation) of Victoza (liraglutide) in all EU/EEA countries. This discontinuation may lead to short-term intermittent shortages in some countries.

Overview of situation

- **Novo Nordisk will discontinue the marketing of Victoza across the EU/EEA by the end of 2026.**
- **Due to the marketing cessation, there may be a risk of short-term intermittent shortages in some countries until the product is no longer marketed.**
- **Timelines for the discontinuation vary from country to country but will be completed in all EU member states by December 2026.**
- **The discontinuation in Malta will occur by December 2025**
- **The marketing cessation is for commercial reasons and not a consequence of any safety or quality related issue.**

Mitigation measures

Novo Nordisk is engaging with the European Medicines Agency and the Medicines Authority on mitigation measures.

Regulatory authorities, physicians, healthcare providers and patient organisations are being informed to help ensure patients transition safely to alternative options for continuity of care.

Patients need to be switched to an alternative treatment in time to avoid the risk of missing doses, which may lead to serious clinical consequences.

Healthcare professionals (HCPs) should consider the following mitigation measures:

- No new patients should be started on Victoza.
- HCPs should switch all patients who are currently on Victoza to alternative GLP-1 analogues or other alternative medication based on existing guidance and clinical judgement.

- HCPs are requested to follow the relevant summary of product characteristics (SmPCs) of the alternative products for dosing recommendations while switching patients to alternative products.
- HCPs are requested to provide clear instructions of usage to the patient, if switched to alternative GLP-1 analogue or other alternative.
- Close glucose monitoring is recommended during the switch to another type or brand of alternative GLP-1 analogue or other alternative and patients should be fully informed about any relevant changes.

Background information

Victoza is indicated for the treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:

• as monotherapy when metformin is considered inappropriate due to intolerance or contra indications

• in addition to other medicinal products for the treatment of diabetes

The product is authorized with the following presentation:

Victoza (liraglutide) 6 mg/mL solution for injection in pre-filled pen

For up-to-date information on the availability of Victoza and the alternatives in a particular EU/EEA country, consult the National Competent Authority.

Call for reporting

Adverse events including medication errors relating to Victoza should be reported to Novo Nordisk https://www.novonordisk.com/patients/report-a-side-effect.html or to local authority through ADR Reporting Website: www.medicinesauthority.gov.mt/adrportal.

Company contact point

Further information can be obtained by contacting Charles de Giorgio Ltd.Triq il-Kan. Karmenu Pirotta, B'Kara, BKR 1114 Malta. Telephone: (+356) 2560 0500 Fax: (+356) 2560 0200 Website: https://charlesdegiorgio.com